Home > PJ  > Letters

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7167 p425-429
29 September 2001

This page
Reprint
Photocopy

Letters

  Consumer information
  Community pharmacy
  Charge exemption
  Locums
  Vaccines
  DOH
  Medication errors
  Health care
  HIV pharmacists
  Pharmacist prescribing
  Antioxidants
  Antifracture therapy


Letters to the Editor

Antifracture therapy

The dual benefits of pravastatin and cod liver oil

From Mr G. P. Walsh, DRCOG

A change of emphasis in cod liver oil’s dual heart and anti-fracture roles might be brought more to pharmacists’ and physicians’ notice by Australasian researchers who now seek an extension to their six-year pravastatin anti-fracture LIPID study mostly in men.1

In this they may be joined by two St Thomas’ hospital researchers who find post- menopausal women, rather than men, most fracture prone.2

Five million Britons have long taken cod liver oil for “arthritis” and “anti-fracture” cures and yet at double the dose (20ml cod liver oil) it might, like pravastatin, also reduce coronary heart disease (CHD).

A dose of 20 to 40ml pure cod liver oil (used clinically for four years on 50 patients from 1982) eased angina, exercise tolerance and increased HDL cholesterol3 and saw many patients 20 years later begin to survive CHD. But lack of a licence seems to dog its cheap use — 40ml liquid pure cod liver oil costs only 50p per day.

Fortunately cod liver oil BP is still licensed but, being fortified 40 per cent with vitamin D to cure rickets, it may risk causing urinary calcium stones; about which 11 years ago your journal issued my warning.

Now, however, with the new anti-fracture emphasis, which even forces waiting list hip fracture surgery to be sent expensively to Germany, the risk may be monitored and worth taking.

References

1. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study. Secondary analysis of a randomised controlled trial. Lancet 2001;357:509–12.

2. Weizbicki AS, Reynolds TM, and reply from Reid IR, Hague W. Statins and fractures. Lancet 2001;357: 1887–9.

3. Walsh GP. The use of omega-3 lipids in coronary heart disease. B J Clin Pract 1984;31:75–6.

Geoffrey Walsh
Blackburn, Lancashire

Back to Top

Previous Topic (Antioxidants)
Send your letter to The Editor


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal